Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 425809 in cognitive impairment due to Alzheimer's disease
2015-005438-24Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2016
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iclepertin in Alzheimer's disease (AD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in ADAS-Cog11. Started Apr 2016; status: completed.
02
Drugs
iclepertin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2015-005438-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005438-24.